skip to content

Biofrontera AG

18:27 on 23/02/2016

Current Price 133.00p | Bid 0.00p | Ask 0.00p | Change 0.00%

Company Overview

Biofrontera AG is a biopharmaceutical company specialising in the development, sale and distribution of drugs and medical cosmetics for the care and treatment of skin diseases. Biofrontera's most important product is Ameluz, a prescription drug which is approved in Europe for the treatment of mild and moderate actinic keratosis (superficial skin cancer) with photodynamic therapy (light therapy). Biofrontera is the first German pharmaceutical start-up company to obtain centralised approval for a drug it has developed itself. The company also plans for Ameluz to be approved for basal cell carcinoma and is currently preparing for approval in other countries, especially in the largest pharmaceutical market in the world, the United States.

Stock Details

EPIC B8F
ISIN DE0006046113
Shares in Issue 27,847,814
Market cap £ 40.38m
Sector Pharmaceuticals & Biotechnology
Indices

Financial Highlights Year Ended 31/12/2014

Turnover €3.10 million
Operating Profit €-9.53 million
Dividend Yield 0.00
Dividend Per Share 0.00
Dividend Cover 0.00
P/E Ratio 0.00
» More Financials

Info Point:

To buy or sell shares call our Dealing Room on 0113 243 6941

Too much jargon? Our glossary will help make sense of things.

Find out more about our Share Dealing Services.

Price Summary

Mid Price ? 0.00p
Bid Price ? 0.00p
Ask Price ? 0.00p
Volume ? 0
Change Today 0.00p
% Change Today 0.00%
Open 0.00p
Previous Close 145.00p
Intraday High 0.00p
Intraday Low 0.00p
52 Week High 202.50p
52 Week Low 135.00p

Intra-Day Chart

More Charts »

Broker Consensus

The broker consensus chart is currently unavailable.

Client Area Access

» Secure Login

» Not registered yet?

Branch Finder

Redmayne-Bentley have High Street branches throughout the UK. Find your nearest branch.